Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma

Internal Medicine Journal

Volumn 35, Issue 2, 2005, Pages 91-96

  Lin, P ^a   Chu, J ^a   Kneebone, A ^a   Moylan, E ^a   Jalaludin, B ^b   Pocock, N ^a   Kiat, H ^a   Rosenfeld, D ^a  

^a LIVERPOOL HOSPITAL   (Australia)

^b SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

Author keywords

18F fluorodeoxyglucose; 67gallium scintigraphy; Coincidence gamma camera positron emission tomography; Lymphoma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM; DIAGNOSTIC AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST; FEMALE; GAMMA CAMERA TOMOGRAPHY; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPHOMA; MALE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS; SPLEEN; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY; VALIDATION PROCESS; ADULT; AGED; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 14844307832     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00744.x     Document Type: Article

References (31)

1. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-6.
2. Wirth A, Grigg A, Wolf M et al. Risk and response adapted treatment for early stage Hodgkin's lymphoma (ESHL): preliminary results of an Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22: 6531.
3. Front D, Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med 1996; 37: 530-2.
4. Larcos G, Farlow D, Antico V, Gruenewald SM, Boyages J. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma. Aust N Z J Med 1994; 24: 5-8.
5. Kaplan WD, Southee AE, Annese ML. Evaluation of low and intermediate grade non-Hodgkin's lymphoma with gallium-67 and thallium-201 imaging (Abstract). J Nucl Med 1990; 31: 793.
6. Waxman AD, Eller D, Ashook G, Ramanna L, Brachman M, Heifetz L et al. Comparison of gallium-67 citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma. J Nucl Med 1996; 37: 46-50.
7. Roach PJ, Cooper RA, Arthur CK, Ravich RB. Comparison of gallium-67 citrate and thallium-201 scintigraphy in the evaluation of non-Hodgkin's lymphoma. Aust N Z J Med 1998; 28: 33-8.
8. Hussain R, Christie DR, Gebski V, Barton MB, Gruenewald SM. The role of the gallium scan in primary extranodal lymphoma. J Nucl Med 1998; 39: 95-8.
9. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995; 25: 60-71.
10. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Sodersrtom KO et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-7.
11. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-9.
12. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-6.
13. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E et al. Lymphoma: role of whole body F-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
14. Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M et al. Whole body F-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) of accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-22.
15. Stumpe KDM, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-8.
16. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 475-81.
17. Carr R, Barrington SF, Madan B, Saunders CA, van der Walt JB et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-6.
18. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN et al. 18-F-Fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16: 603-9.
19. De Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8: 57-60.
20. Bangerter M, Moog F, Griesshammer M, Merkle E, Hafner M, Ellenrieder V et al. Role of whole-body FDG-PET in predicting relapse in residual masses after treatment of lymphoma. Br J Haematol 1998; 102: 148.
21. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with F-18 FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19: 1055-63.
22. Krausz Y, Strauss HW, Goris ML. Comparison of FDG-PET and gallium scan in staging and follow-up of patients with Hodgkin's disease (Abstract). J Nucl Med 1999; 40: 62.
23. Patton JA, Turkington TG. Coincidence imaging with a dual-head scintillation camera. J Nucl Med 1999; 40: 432-41.
24. Lewellen TK, Miyaoka RS, Swan WL. PET imaging using dual-headed gamma cameras: an update. Nucl Med Commun 1999; 20: 5-12.
25. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic diagnosis with 2-Fuoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998; 207: 431-7.
26. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of the lymphoma. Cancer 2002; 94: 879-88.
27. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 262-8.
28. National Cancer Institute. Sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathol classification project. Cancer 1982; 49: 2112-35.
29. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging. Cancer Res 1971; 31: 1860-1.
30. 18F-fluoro-2- deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002; 9: 321-5.
31. Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Semin Nucl Med 2001; 31: 177-90.